Press Release


Expansion significantly increases laboratory space, creating new job opportunities in the area

OXFORD, United Kingdom, 26 April 2018 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that it has expanded into a new laboratory and office space at The Oxford Science Park, to enhance its research and development (R&D) capabilities and to facilitate growth of the Company.

Following its inception in 2016, Evox has continued to advance its groundbreaking exosome research. This expansion reflects the growing interest and demand in the exosome-based biotherapeutics field and will provide access to the R&D facilities and equipment needed to accelerate the Company’s growth.

As part of the move, Evox is expecting to create over a dozen new job opportunities in the area over the near-term.

The new 5,800 square foot space significantly increases the Company’s overall footprint and includes state-of-the-art laboratories, providing cleanroom capabilities and a tissue culture / process development laboratory suitable to prepare material for pre-clinical studies.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “We are pleased to be moving into our new, state-of-the-art facilities at The Oxford Science Park. This expansion will accommodate our increase in R&D and expanding pre-clinical pipeline of exosome biotherapeutics.

Our research stems from the innovative work carried out at the University of Oxford; therefore we look forward to the opportunities provided by this expansion to continue to attract talented new employees in the Oxford region.”

Piers Scrimshaw-Wright, Managing Director of The Oxford Science Park, added: “We are delighted to see Evox Therapeutics expanding on The Oxford Science Park as its R&D progresses. It is one of several University of Oxford spin-outs on the Park, cementing our reputation as the place to locate for life sciences business in Oxford.”

For enquiries, please contact:

Dr. Antonin de Fougerolles, Chief Executive Officer           01865 819140

Dr. Per Lundin, Co-Founder and Chief Operating Officer   01865 819140

Brett Pollard / Natalie Garland-Collins

FTI Consulting

+44 (0) 20 3727 1000

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics. Backed by Oxford Sciences Innovation and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.